July 5, 2014- Interviewed by Steven E. Greer, MD
The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas” being developed by engineers at Boston University and medical doctors at Massachusetts General hospital. We interviewed Ed Damiano, PhD, the lead biomedical engineer, and Steven Russell, MD PhD, the lead endocrinologist.
In Part 3, we asked them how their small lab funded only by the NIH succeeded at developing the bionic pancreas when large companies, such as Roche, Medtronic, Abbott, and JNJ all failed.
October 19, 2014- Interviewed by Steven E. Greer, MD
Did you know that one out of three Americans think that they are “gluten intolerant”. Of those 100 Million people, only 13 Million really have a medical problem caused by gluten.
Alessio Fasano, MD, director of the Center for Celiac Research and Treatment at MassGeneral Hospital for Children, is the man who started all of the gluten hype back in 2003 with a paper in the Archives of Internal Medicine. Hoping to reduce some of the current “gluten hysteria,” he has written a book explaining what gluten is, who can and can’t eat it, and why. We interviewed him.
Book reviews, Diabetes, Gastroenterology/Hepatology, Harvard affiliates, Internal medicine, Internal medicine/microbiology immunology, NEJM, Nutrition, Pediatrics, Policy | apples49 | 
June 4, 2015 12:39 pm | 
Comments (0)
April 21, 2015- By Steven E. Greer, MD
Brigham and Women’s Hospital in Boston, part of the Harvard University network of hospitals, has begun a rather perplexing public relations campaign. On national TV shows, such as PBS’ Frontline, Read more »
March 18, 2015- Op-Ed by Steven E. Greer, MD
The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data making the national news came from the PCSK9-antibody drugs (evolocumab and alirocumab) that dramatically Read more »
March 23, 2015- Interviewed by Steven E. Greer, MD
We interviewed the Principal Investigator of the PROMISE trial, Pamela Douglas, MD from Duke. Read more »
July 28, 2014- Interviewed by Steven E. Greer, MD
Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote with his sister, Monica Gandhi, MD, discussing the current state of therapy for HIV-infected patients. He then addresses the ways to prevent HIV infection either after or before exposure.
July 28, 2014- Interviewed by Steven E. Greer, MD
Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote with his sister, Monica Gandhi, MD, discussing the current state of therapy for HIV-infected patients. He then addresses limitations of the existing drugs and how future medications can improve.
July 2, 2014- Interviewed by Steven E. Greer, MD
The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas” being developed by engineers at Boston University and medical doctors at Massachusetts General hospital. We interviewed Ed Damiano, PhD, the lead biomedical engineer, and Steven Russell, MD PhD, the lead endocrinologist. In Part 1, they review the clinical data.
The research was funded by the NIH and not a medical device or drug company. The researchers selected the components based on merit. They chose the Dexcom G4 Platinum continuous glucose sensor and a Tandem Diabetes t:slim pump, and used software that ran on a standard Apple iPhone 4S.
In Part 2, the team discusses the details of the pivotal study, that could be concluded by 2016, allowing for an FDA approval by 2017. Industry partners yet to be determined would be involved. However, the final marketed product will not require any particular smartphone to be used by the patient.
Boston University, Diabetes, Endocrinology, FDA, Harvard affiliates, Internal medicine, Medical Devices, NEJM, NIH, Nutrition, Pediatrics, Preventive Medicine, Wound Care | apples49 | January 16, 2015 10:36 pm | Comments (0)
Interviewed by Steven E. Greer, MD
March 19, 2013
The upcoming ASCO meeting will be dominated by numerous presentations relating to new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early Phase 1 data in non-small cell lung cancer, renal cancer, and melanoma demonstrated such impressive sustained tumor responses that they papers were published in the New England Journal of Medicine. Antoni Ribas, MD of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing some of these new molecules. In the video interview, he explains the mechanisms of action, reviews data published so far, and previews new data to be seen at ASCO.
Interviewed by Steven Greer MD
Under the ACA health insurance reform laws, approximately 16 million new Medicaid patients will be added to the system in a few years. Medicaid pays hospitals and doctors much less than Medicare and private insurance. Will increasing the mix of Medicaid increase the financial distress of medical centers?
Benjamin Sommers, MD PhD Internist and Assistant Professor of Public Health at Harvard addresses this question.
